Koesten Hirschmann & Crabtree’s Adaptimmune Therapeutics ADAP Stock Holding History

Koesten Hirschmann & Crabtree’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-47	Closed	-$7	–	44
2025 Q3	$7	Hold	47	–	–	﹤0.01%	260
2025 Q2	$12	Buy	+47	New	+$13	﹤0.01%	342

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Koesten Hirschmann & Crabtree's ADAP Position: Q4 2025 in Review

Koesten Hirschmann & Crabtree sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 47 shares — an estimated $7 sold.

Koesten Hirschmann & Crabtree first reported a position in ADAP in Q2 2025 and held it in 2 quarters. The position peaked at $12 in Q2 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Koesten Hirschmann & Crabtree reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Koesten Hirschmann & Crabtree sold 47 Adaptimmune Therapeutics shares in Q4 2025, an estimated $7.
Koesten Hirschmann & Crabtree first reported a position in Adaptimmune Therapeutics in Q2 2025 and held it in 2 quarters.
Koesten Hirschmann & Crabtree's Adaptimmune Therapeutics position peaked at $12 in Q2 2025.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Koesten Hirschmann & Crabtree's 13F filing for Q4 2025, filed 9 Feb 2026.